Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Weidong Han

Showing results (1-10 of 391) with videos related to

Pageof 40
Sort By:
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|March 26, 2016
[Anti-CD19 chimeric antigen receptor T cells (CART-19) for hemotological malignancies therapy]Hejin Jia, Weidong Han
Science China. Life Sciences|May 31, 2015
Innovative and propagable translational research model established for cell-based therapy at Chinese PLA General HospitalWeidong Han, Xiaobing Fu
Current Protein & Peptide Science|May 2, 2015
Editorial: perspectives on strategies for overcoming cancer therapy resistanceZhiqiang Wu, Weidong Han
Chinese Journal of Cancer|May 13, 2015
Cytokine-induced killer (CIK) cells: from basic research to clinical translationYelei Guo, Weidong Han
Biomarker Research|February 2, 2018
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapyZhenguang Wang, Weidong Han
Science China. Life Sciences|November 25, 2017
CART trials are going aheadJianshu Wei, Weidong Han
Cancer Innovation|September 29, 2025
Epi-Immunotherapy in Cancer Treatment: Mechanisms, Clinical Progress, and Future DirectionsNannan Lu, Guanghua Rong, Weidong Han
Cellular & Molecular Immunology|June 12, 2023
Optimized collaboration of the first and third signals endows robust activity to T cells within the immunocompetent tumor microenvironmentJianshu Wei, Xin Lin, Weidong Han
Journal of Immunology Research|March 22, 2016
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsYelei Guo, Yao Wang, Weidong Han
Science China. Life Sciences|March 25, 2016
Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in ChinaCan Luo, Jianshu Wei, Weidong Han
Pageof 40

Showing results (1-10 of 391) with videos related to

Sort By:
Pageof 40
Zhonghua Xue Ye Xue Za Zhi = Zhonghua Xueyexue Zazhi|March 26, 2016
[Anti-CD19 chimeric antigen receptor T cells (CART-19) for hemotological malignancies therapy]Hejin Jia, Weidong Han
Science China. Life Sciences|May 31, 2015
Innovative and propagable translational research model established for cell-based therapy at Chinese PLA General HospitalWeidong Han, Xiaobing Fu
Current Protein & Peptide Science|May 2, 2015
Editorial: perspectives on strategies for overcoming cancer therapy resistanceZhiqiang Wu, Weidong Han
Chinese Journal of Cancer|May 13, 2015
Cytokine-induced killer (CIK) cells: from basic research to clinical translationYelei Guo, Weidong Han
Biomarker Research|February 2, 2018
Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapyZhenguang Wang, Weidong Han
Science China. Life Sciences|November 25, 2017
CART trials are going aheadJianshu Wei, Weidong Han
Cancer Innovation|September 29, 2025
Epi-Immunotherapy in Cancer Treatment: Mechanisms, Clinical Progress, and Future DirectionsNannan Lu, Guanghua Rong, Weidong Han
Cellular & Molecular Immunology|June 12, 2023
Optimized collaboration of the first and third signals endows robust activity to T cells within the immunocompetent tumor microenvironmentJianshu Wei, Xin Lin, Weidong Han
Journal of Immunology Research|March 22, 2016
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and ProspectsYelei Guo, Yao Wang, Weidong Han
Science China. Life Sciences|March 25, 2016
Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in ChinaCan Luo, Jianshu Wei, Weidong Han
Pageof 40